Analysts Boost Price Targets for Exagen, Amgen, and Arvinas
Analysts are optimistic about several healthcare companies, including Exagen (XGN), Amgen (AMGN), and Arvinas Holding Company (ARVN). Mark Massaro from BTIG reiterated a Buy rating on Exagen with a price target of $9.00, citing the company's strong Q2 performance and lower cash risk. The current analyst consensus on Exagen is a Strong Buy with an average price target of $9.00, representing a 56.5% upside from current levels.
Piper Sandler analyst David Amsellem also reiterated a Buy rating on Amgen today, setting a price target of $427.00. The company's shares closed last Tuesday at $390.02. Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $367.94, which is a -3.4% downside from current levels.
Edward Tenthoff from Piper Sandler reiterated a Buy rating on Arvinas Holding Company, with a price target of $20.00. The company's shares closed last Tuesday at $9.00, close to its 52-week low of $7.53. Arvinas Holding Company has an analyst consensus of Moderate Buy, with a price target consensus of $14.13, representing a 69.6% upside from current levels.